Recent challenges in insulin delivery systems: A review

Indian Journal of Pharmaceutical Sciences

Volumn 70, Issue 3, 2008, Pages 278-286

  Al Tabakha, M ^a   Arida, A ^b  

^a AJMAN UNIVERSITY   (United Arab Emirates)

^b PHILADELPHIA UNIVERSITY   (Jordan)

Author keywords

Diabetes mellitus; Exubera ; Insulin; Non invasive delivery systems

Indexed keywords

GLUCOSE; HUMAN INSULIN; INSULIN; NEUTRAL INSULIN; RECOMBINANT HUMAN INSULIN;

CONTINUOUS INFUSION; COUGHING; DIABETIC PATIENT; DRUG DELIVERY SYSTEM; DRUG SAFETY; EUROPE; HUMAN; HYPOGLYCEMIA; INFECTION; INJECTION PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN TREATMENT; JET INJECTOR; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PILL; REVIEW; UNITED STATES;

EID: 52149114069     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.42968     Document Type: Review

References (67)

1. Rosenfeld L. Insulin: Discovery and controversy. Clin Chem 2002;48:2270-88.
2. Verge D. Biotechnological and administration innovations in insulin therapy. Med Sci (Paris) 2004;20:986-98.
3. Walsh G. Therapeutic insulins and their large-scale manufacture. Appl Microbiol Biotechnol 2005;67:151-9.
4. Saltiel AR, Khan CR. Insulin signaling and regulation of glucose and lipid metabolism. Nature 2001;414:799-806.
5. Rotte M, Baerecke C, Pottag G, Klose S, Kanneberg E, Heinze HJ, et al. Insulin affects the neuronal response in the medial temporal lobe in humans. Neuroendocrinology 2005;81:49-55.
6. DeLuca AJ, Saulle LN, Aronow WS, Ravipati G, Weiss MB. Prevalence of silent myocardial ischemia in persons with diabetes mellitus or impaired glucose tolerance and association of hemoglobin A1c with prevalence of silent myocardial ischemia. Am J Cardiol 2005;95:1472-4.
7. Schechter R, Beju D, Miller KE. The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochem Biophys Res Commun 2005;334:979-86.
8. Campbell RK, White JR Jr. Insulin therapy in type 2 diabetes. J Am Pharm Assoc (Wash) 2002;42:602-11.
9. Rolla AR, Rakel RE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther 2005;27:1113-25.
10. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance: The Australian diabetes, obesity, and lifestyle study. Diabetes Care 2002;25:829-34.
11. Rizvi AA. Type 2 diabetes: epidemiologic trends, evolving pathogenic concepts, and recent changes in therapeutic approach. South Med J 2004;97:1027-8.
12. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes, estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
13. Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, Khalil MZ, et al. Diabetes mellitus in Saudi Arabia. Saudi Med J 2004;25:1603-10.
14. Osei K. Global epidemic of type 2 diabates: Implications for developing countries. Ethn Dis 2003;13:S102-6.
15. th ed. New York: McGraw-Hill; 2002. p. 1335-58.]
16. Pradeepa R, Mohan V. The changing scenario of the diabetes epidemic: Implications for India. Indian J Med Res 2002;116:121-32.
17. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: A randomised proof-of-concept study. Lancet 2001;357:331-5.
18. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabetes Med 2003;20:886-98.
19. Hermansen K, Rönnemaa T, Petersen AH, Bellaire S, Adamson U. Intensive therapy with inhaled insulin via the AERx® insulin diabetes management system: A 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004;27:162-7.
20. Schwartz S, Hassman D, Shelmet J, Sievers R, Weinstein R, Liang J, et al. Multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6 mm needle versus a 29 gauge x 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther 2004;26:1663-78.
21. Teo MA, Shearwood C, Ng KC, Lu J, Moochhala S. In vitro and in vivo characterization of MEMS microneedles. Biomed Microdevices 2005;7:47-52.
22. American Diabetes Association. Insulin administration. Diabetes Care 2001;24:1984-7.
23. Gnanalingham MG, Newland P, Smith CP. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child 1998;79:59-62.
24. Alemzadeh R, Palma-Sisto P, Parton EA, Holzum MK. Continuous subcutaneous insulin infusion and multiple dose of insulin regimen display similar patterns of blood glucose excursions in pediatric type 1 diabetes. Diabetes Technol Ther 2005;7:587-96.
25. Unger J. Principles of intensive insulin therapy. Hosp Physician 1994;18:8-20.
26. Williams AS. Teaching nonvisual diabetes self care: Choosing appropriate tools and techniques for visually impaired individuals. Diabetes Spectrum 1997;10:128-34.
27. Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess 2004;8:1-171.
28. Sullivan-Bolyai S, Knafl K, Tamborlane W, Grey M. Parents' reflections on managing their children's diabetes with insulin pumps. J Nurs Scholarsh 2004;36:316-23.
29. Price JP, Kruger DF, Saravolatz LD, Whitehouse FW. Evaluation of the insulin jet injector as a potential source of infection. Am J Infect Control 1989;17:258-63.
30. Jovanovic-Peterson L, Sparks S, Palmer JP, Peterson CM. Jet-injected insulin is associated with decreased antibody production and postprandial glucose variability when compared with needle-injected insulin in gestational diabetic women. Diabetes Care 1993;16:1479-84.
31. American Diabetic Association. Position statement: Insulin administration. Diabetes Care 1997;20:S46-9.
32. Schneider U, Birnbacher R, Schober E. Painfulness of needle and jet injection in children with diabetes mellitus. Eur J Pediatr 1994;153:409-10.
33. Logwin S, Conget I, Jansa M, Vidal M, Nicolau C, Gomis R. Human insulin-induced lipoatrophy: Successful treatment using a jet-injection device. Diabetes Care 1996;19:255-6.
34. Leblanc H, Passa P. The insulin pen injector: Toward its rational development and utilization. Diabetes Metab 1993;19:58-60.
35. Toraishi K, Yuizono Y, Nakamura N, Kato S, Aoki T, Ashida K, et al. Force requirements and insulin delivery profiles of four injection devices. Diabetes Technol Ther 2005;7:629-35.
36. Puder JJ, Atar M, Muller B, Pavan M, Keller U. Using insulin pen needles up to five times does not affect needle tip shape nor increase pain intensity. Diabetes Res Clin Pract 2005;67:119-23.
37. Coonrod BA. Insulin syringes and pens: Finding the best match for your patients' needs. Clin Diabetes 1997;15:114-20.
38. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Case study: Contrasting challenges of insulin pump therapy in a toddler and adolescent with type 1 diabetes. Diabetes Educ 2005;31:584-90.
39. Andersson PO, Wikby A, Hornquist JO. Influence of insulin pen injection frequency on quality of life. Diabetes Care 1990;13:1135-6.
40. Jeandidier N, Boivin S. Current status and future prospects of parenteral insulin regimens, strategies and delivery systems for diabetes treatment. Adv Drug Deliv Rev 1999;35:179-98.
41. Gall MA, Mathiesen ER, Skott P, Musaeus L, Damm S, Beck-Nielsen H, et al. Effect of multiple insulin injections with a pen injector on metabolic control and general well-being in insulin-dependent diabetes mellitus. Diabetes Res 1989;11:97-101.
42. Albano S; Orbiter study group. Assessment of quality of treatment in insulin-treated patients with diabetes using a pre-filled insulin pen. Acta Biomed Ateneo Parmense 2004;75:34-9.
43. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 2004;26:1498-505.
44. Farr SJ, Kellaway IW, Taylor G. Drug delivery to the respiratory tract. In: Florence AT, Salole EG, editors. Routes of drug administration, Topics in Pharmacy (Vol.2). London: Wright Publishing Company; 1990. p. 48-77.
45. Fineberg SE. Diabetes therapy trials with inhaled insulin. Exp Opin Investig Drugs 2006;15:743-62.
46. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004;43:781-801.
47. Cernea S, Raz I. Noninjectable methods of insulin administration. Drugs Today (Barc) 2006;42:405-24.
48. Barnett AH. Exubera inhaled insulin: A review. Int J Clin Pract 2004;58:394-401.
49. Mandal TK. Inhaled insulin for diabetes mellitus. Am J Health Syst Pharm 2005;62:1359-64.
50. Quattrin T. Inhaled insulin: Recent advances in the therapy of type 1 and 2 diabetes. Expert Opin Pharmacother 2004;5:2597-604.
51. Aguiar MM, Rodrigues JM, Silva Cunha A. Encapsulation of insulin-cyclodextrin complex in PLGA microspheres: A new approach for prolonged pulmonary insulin delivery. J Microencapsul 2004;21:553-64.
52. Kwon JH, Lee BH, Lee JJ, Kim CW. Insulin microcrystal suspension as a long-acting formulation for pulmonary delivery. Eur J Pharm Sci 2004;22:107-16.
53. Randall O. Novo Nordisk agrees to $55M for Aradigm.s insulin program. Bio World Today 2004;15:1-2.
54. Venugopalan P, Sapre A, Venkatesan N, Vyas SP. Pelleted bioadhesive polymeric nanoparticles for buccal delivery of insulin: Preparation and characterization. Pharmazie 2001;56:217-9.
55. Xu HB, Huang KX, Zhu YS, Gao QH, Wu QZ, Tian WQ, et al. Hypoglycemic effect of a novel insulin buccal formulation on rabbits. Pharmacol Res 2002;46:459-67.
56. Modi P, Mihic M, Lewin A. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist system. Diabetes Metab Res Rev 2002;8:S38-42.
57. Guevara-Aguirre J, Guevara M, Saavedra J, Mihic M, Modi P. Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents. Diabetes Technol Ther 2004;6:1-8.
58. Rodrigues JM Jr, de Melo LK, de Matos JC, de Aguiar MM, da Silva Cunha A Jr. The effect of cyclodextrins on the in vitro and in vivo properties of insulin-loaded poly (D,L-lactic-co-glycolic acid) microspheres. Artif Organs 2003;27:492-7.
59. Kidron M, Dinh S, Menachem Y, Abbas R, Variano B, Goldberg M, et al. A novel per-oral insulin formulation: Proof of concept study in non-diabetic subjects. Diabetes Med 2004;21:354-7.
60. Jederstrom G, Andersson A, Grasjo J, Sjoholm I. Formulating insulin for oral administration: preparation of hyaluronan-insulin complex. Pharm Res 2004;21:2040-7.
61. Morcol T, Nagappan P, Nerenbaum L, Mitchell A, Bell SJ. Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. Int J Pharm 2004;277:91-7.
62. Gordon SJ. Development of oral insulin: Progress and current status. Diabetes Metab Res Rev 2002;18:S29-37.
63. Arbit E. The physiological rationale for oral insulin administration. Diabetes Technol Ther 2004;6:510-7.
64. King MJ, Badea I, Solomon J, Kumar P, Gaspar KJ, Foldvari M. Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol Ther 2002;4:479-88.
65. Desai TA, West T, Cohen M, Boiarski T, Rampersaud A. Nanoporous microsystems for islet cell replacement. Adv Drug Deliv Rev 2004;56:1661-73.
66. Sekigami T, Shimoda S, Nishida K, Matsuo Y, Ichimori S, Ichinose K, et al. Comparison between closed-loop portal and peripheral venous insulin delivery systems for an artificial endocrine pancreas. J Artif Organs 2004;7:91-100.
67. Green A, Christian HN, Pramming SK. The changing world demography of type 2 diabetes. Diabetes Metab Res Rev 2003;19:3-7.